OverviewSuggest Edit

Castle Biosciences is a company developing and commercializing diagnostic and prognostic tests for dermatologic cancers. It offers products for diagnosing cutaneous melanoma (DecisionDx-Melanoma, DecisionDx DiffDx-Melanoma, and DecisionDx-CMSeq), solutions for the prognosis and diagnosis of uveal melanoma (DecisionDx-UM, DecisionDx-UMSeq, and DecisionDx-PRAME), and a predictor of metastasis DecisionDx-SCC.
TypePublic
Founded2008
Websitecastlebiosciences.com

Latest Updates

Employees (est.) (Dec 2019)133
Revenue (FY, 2020)$62.6 M(+21%)
Share Price (Sept 2021)$75.8
Cybersecurity ratingBMore

Key People/Management at Castle Biosciences

Derek Maetzold

Derek Maetzold

Founder, President, and CEO
Frank Stokes

Frank Stokes

Chief Financial Officer
Toby Juvenal

Toby Juvenal

Chief Commercial Officer
Kristen Oelschlager

Kristen Oelschlager

Chief Operations Officer
Bernhard E. Spiess

Bernhard E. Spiess

Chief Business Officer
Bob Cook

Bob Cook

Senior Vice President, Research & Development
Show more

Castle Biosciences Office Locations

Castle Biosciences has an office in Phoenix
Phoenix, AZ, US
3737 N 7th St #160
Show all (1)

Castle Biosciences Financials and Metrics

Castle Biosciences Revenue

Embed Graph
View revenue for all periods
Castle Biosciences's revenue was reported to be $62.65 m in FY, 2020
USD

Revenue (Q1, 2021)

22.8m

Gross profit (Q1, 2021)

19.8m

Gross profit margin (Q1, 2021), %

86.7%

Net income (Q1, 2021)

(4.3m)

EBIT (Q1, 2021)

(4.3m)

Market capitalization (9-Sept-2021)

1.9b

Closing stock price (9-Sept-2021)

75.8

Cash (31-Mar-2021)

407.0m
Castle Biosciences's current market capitalization is $1.9 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

13.8m22.8m51.9m62.6m

Revenue growth, %

66%128%

Cost of goods sold

4.9m5.3m7.3m9.7m

Gross profit

8.8m17.5m44.6m53.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

3.7m4.0m3.7m8.7m10.7m14.8m17.4m12.7m15.2m22.8m

Cost of goods sold

1.3m1.3m1.4m1.6m2.0m1.7m2.4m2.1m2.5m3.0m

Gross profit

2.4m2.7m2.4m7.1m8.7m13.1m15.0m10.6m12.7m19.8m

Gross profit Margin, %

66%67%64%82%81%88%86%83%84%87%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.2m4.5m98.8m409.9m

Accounts Receivable

4.7m12.1m14.6m12.8m

Prepaid Expenses

515.5k675.6k2.0m4.8m

Inventories

304.6k882.2k1.2m2.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

16.2m17.5m94.5m98.7m179.8m183.1m407.0m

Accounts Receivable

9.2m9.7m12.4m14.6m12.5m12.6m14.3m

Prepaid Expenses

741.4k774.9k2.2m2.1m1.7m3.7m3.1m

Inventories

809.3k550.9k821.7k1.2m1.7m1.7m2.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(12.4m)(6.4m)5.3m(10.3m)

Depreciation and Amortization

310.8k323.0k358.0k472.0k

Inventories

(115.6k)(577.7k)(355.0k)(980.0k)

Accounts Payable

370.9k197.2k557.0k169.0k
USDFY, 2017

Revenue/Employee

215.5k

Debt/Equity

-0.4 x

Debt/Assets

1.9 x

Financial Leverage

-0.2 x
Show all financial metrics

Castle Biosciences Operating Metrics

Q1, 2019

Clinical Samples Processed to Date

40 k
Show all operating metrics

Castle Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Castle Biosciences Online and Social Media Presence

Embed Graph

Castle Biosciences News and Updates

Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

SALT LAKE CITY, April 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has signed a definitive agreement to sell the Myriad myPath Melanoma, LLC, Laboratory, which is the laboratory that offers the myPath Melan…

Can Castle Biosciences Stock Rebound After The Recent 24% Drop?

The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. We believe the stock, after the recent drop, may trend higher in the near term. The recent drop can largely be...

Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market o…

Castle Biosciences to Present at Upcoming Investor Conferences

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the following upcomin…

Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium, taking place f…

VC-backed Castle Biosciences goes public

Friendswood, Texas-based Castle Biosciences Inc, a dermatological cancer company, has raised $64 million for its IPO after pricing its 4 million shares at $16 per share. The stock began trading July 25, 2019 on the NASDAQ under the ticker symbol "CSTL." SVB Leerink and Baird are the lead underwriter…

Castle Biosciences Blogs

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019

The post Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019 appeared first on Castle Biosciences, Inc..

Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology

The post Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology appeared first on Castle Biosciences, Inc..

Castle Biosciences Added to NASDAQ Biotechnology Index

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Dec. 18, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that the Company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to the market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed t…

Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations

Data was presented during the 16th International Congress of the Society for Melanoma Research FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 25, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions…

Castle Biosciences to Present at Upcoming Investor Conferences

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 20, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at t…

Castle Biosciences Reports Third Quarter 2019 Results

Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018 Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 2018 Q3 2019 gross margin increased to 88%, up from 64% in Q3 2018 December 2019 salesforce expansion Presented clinical validation data…
Show more

Castle Biosciences Frequently Asked Questions

  • When was Castle Biosciences founded?

    Castle Biosciences was founded in 2008.

  • Who are Castle Biosciences key executives?

    Castle Biosciences's key executives are Derek Maetzold, Frank Stokes and Toby Juvenal.

  • How many employees does Castle Biosciences have?

    Castle Biosciences has 133 employees.

  • What is Castle Biosciences revenue?

    Latest Castle Biosciences annual revenue is $62.6 m.

  • What is Castle Biosciences revenue per employee?

    Latest Castle Biosciences revenue per employee is $471 k.

  • Who are Castle Biosciences competitors?

    Competitors of Castle Biosciences include Pharma Mar, Biocept and Veracyte.

  • Where are Castle Biosciences offices?

    Castle Biosciences has an office in Phoenix.

  • How many offices does Castle Biosciences have?

    Castle Biosciences has 1 office.